SCHEMBL12188033

SCHEMBL12188033

COOCc1ccc2c(c1)nc(N)c1nn(Cc3ccccc3F)c(=O)n12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 10/20 0.39
▸ ADORA2A P29274 8/20 0.39
▸ ADORA1 P30542 5/20 0.39
▸ KCNH2 Q12809 1/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ TP53 P04637 2/20 0.34
▸ HPGD P15428 2/20 0.34
▸ TSHR P16473 2/20 0.34
▸ LMNA P02545 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ MAPT P10636 2/20 0.34
▸ ALDH1A1 P00352 3/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ BTK Q06187 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ BLM P54132 1/20 0.34
▸ L3MBTL1 Q9Y468 1/20 0.34
▸ CYP1A2 P05177 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12188084 0.88 ADORA2A (0.43) ADORA3ADORA2AADORA1ALDH1A1POLB
SCHEMBL12165590 0.86 ADORA2A (0.41) ADORA3ADORA2AADORA1SMN1; SMN2TP53
SCHEMBL12165759 0.84 ADORA3 (0.47) ADORA3ADORA2AADORA1SMN1; SMN2TP53
SCHEMBL14922476 0.82 LMNA (0.44) ADORA3ADORA2AADORA1KCNH2TSHR
SCHEMBL12188019 0.80 ADORA2A (0.43) ADORA3ADORA2AADORA1
SCHEMBL12165508 0.74 ADORA3 (0.53) ADORA3ADORA2AADORA1TP53ALDH1A1
SCHEMBL12165525 0.74 ADORA2A (0.42) ADORA3ADORA2AADORA1
SCHEMBL12165735 0.73 ALDH1A1 (0.56) ADORA3ADORA2AADORA1ALDH1A1POLB
SCHEMBL12165526 0.73 ADORA3 (0.48) ADORA3ADORA2AADORA1TP53MAPT
SCHEMBL12188014 0.72 ADORA3 (0.55) ADORA3ADORA2AADORA1SMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232086-A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY MERCK SHARP & DOHME CORP. (US) 2012-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232086-A1 FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY ADORA2A, ADORA3, ADORA1 ADORA3 2/4885ADORA2A 1/4885ADORA1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback